ASCPT Task Force for advancing pharmacometrics and integration into drug development
- PMID: 20648032
- DOI: 10.1038/clpt.2010.141
ASCPT Task Force for advancing pharmacometrics and integration into drug development
Erratum in
- Clin Pharmacol Ther. 2010 Dec;88(6):883.. Allerheiligan, S [corrected to Allerheiligen, S]
Abstract
Traditionally, medical and biostatistical experts have played a central role in ensuring validity of pharmaceutical testing. The science of pharmacometrics provides powerful approaches for supporting important drug development and regulatory decisions. Numerous case studies published by academic, industry, and US Food and Drug Administration scientists attest to the significant contribution of pharmacometrics to decision making. The economic and public health benefits of applying this discipline to clinical trials far outweigh the cost associated with its implementation. The purpose of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Task Force is to build on the momentum and accelerate dissemination of its impact and adoption into drug development. We describe briefly the contributions of pharmacometrics and the specific goals of the Task Force.
Similar articles
-
Experiences with learning and confirming in drug and biological development.Clin Pharmacol Ther. 2010 Aug;88(2):161-3. doi: 10.1038/clpt.2010.50. Clin Pharmacol Ther. 2010. PMID: 20648033 Review.
-
Biostatistics and pharmacometrics: quantitative sciences to propel drug development forward.Clin Pharmacol Ther. 2010 Aug;88(2):141-4. doi: 10.1038/clpt.2010.136. Clin Pharmacol Ther. 2010. PMID: 20648027 No abstract available.
-
Pharmacometrics at FDA: evolution and impact on decisions.Clin Pharmacol Ther. 2007 Jul;82(1):97-102. doi: 10.1038/sj.clpt.6100234. Epub 2007 May 30. Clin Pharmacol Ther. 2007. PMID: 17538553 Review.
-
Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation.Clin Pharmacol Ther. 2013 Jun;93(6):515-25. doi: 10.1038/clpt.2013.32. Epub 2013 Feb 12. Clin Pharmacol Ther. 2013. PMID: 23571772
-
Advancing pharmacometrics and systems pharmacology.Clin Pharmacol Ther. 2012 Nov;92(5):535-7. doi: 10.1038/clpt.2012.151. Clin Pharmacol Ther. 2012. PMID: 23085873 Free PMC article.
Cited by
-
Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis.CPT Pharmacometrics Syst Pharmacol. 2012 Oct 17;1(10):e11. doi: 10.1038/psp.2012.10. CPT Pharmacometrics Syst Pharmacol. 2012. PMID: 23887363 Free PMC article.
-
Comparisons of Analysis Methods for Proof-of-Concept Trials.CPT Pharmacometrics Syst Pharmacol. 2013 Jan 16;2(1):e23. doi: 10.1038/psp.2012.24. CPT Pharmacometrics Syst Pharmacol. 2013. PMID: 23887593 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources